The antidiabetics market in Saudi Arabia is expected to reach a projected revenue of US$ 1,103.3 million by 2033. A compound annual growth rate of 6.2% is expected of Saudi Arabia antidiabetics market from 2026 to 2033.
AstraZeneca PLC, Bayer AG, Takeda Pharmaceutical Co Ltd, Eli Lilly and Co, Boehringer Ingelheim, Bristol-Myers Squibb Co, Pfizer Inc, Johnson & Johnson, Merck & Co Inc, Novartis AG ADR
Other key industry trends
In terms of revenue, Saudi Arabia accounted for 0.6% of the global antidiabetics market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Middle East & Africa, Saudi Arabia antidiabetics market is projected to lead the regional market in terms of revenue in 2033.
UAE is the fastest growing regional market in Middle East & Africa and is projected to reach USD 455.0 million by 2033.
Saudi Arabia's antidiabetics market is showing strong momentum, attributed to considerable government investment in pharmaceutical infrastructure and education.
Public health organizations, including the Saudi Diabetes & Endocrine Association, are actively engaged in awareness campaigns aimed at early diagnosis and treatment.
At the same time, investments in R&D and the adoption of modern drug delivery systems are expected to enhance patient compliance and improve outcomes, further contributing to the market’s growth trajectory.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Antidiabetics Market will help companies and investors design strategic landscapes.
Glp-1 Receptor Agonists was the largest segment with a revenue share of 56.03% in 2025.
Horizon Databook has segmented the Saudi Arabia antidiabetics market based on insulin, glp-1 receptor agonists, dpp- 4 inhibitors, sglt2 inhibitors covering the revenue growth of each sub-segment from 2021 to 2033.
Saudi Arabia's antidiabetics market is showing strong momentum, attributed to considerable government investment in pharmaceutical infrastructure and education.
Public health organizations, including the Saudi Diabetes & Endocrine Association, are actively engaged in awareness campaigns aimed at early diagnosis and treatment.
At the same time, investments in R&D and the adoption of modern drug delivery systems are expected to enhance patient compliance and improve outcomes, further contributing to the market’s growth trajectory.
Saudi Arabia Antidiabetics Market Drug Class Outlook (Revenue, USD Million , 2021-2033)
Insulin
GLP-1 Receptor Agonists
DPP- 4 Inhibitors
SGLT2 Inhibitors
Others
Saudi Arabia Antidiabetics Market Diabetes Type Outlook (Revenue, USD Million , 2021-2033)
Type 1
Type 2
Saudi Arabia Antidiabetics Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Saudi Arabia Antidiabetics Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
Oral
Subcutaneous
Intravenous
Reasons to subscribe to antidiabetics market databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of antidiabetics market databook
Our clientele includes a mix of antidiabetics market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia antidiabetics market, including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia antidiabetics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Saudi Arabia Antidiabetics Market, 2021-2033 (US$M)